233 related articles for article (PubMed ID: 34996330)
1. Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies.
Papamichael K; Cheifetz AS
Expert Opin Drug Metab Toxicol; 2021 Dec; 17(12):1423-1431. PubMed ID: 34996330
[TBL] [Abstract][Full Text] [Related]
2. Individualized Dosing of Therapeutic Monoclonal Antibodies-a Changing Treatment Paradigm?
Strik AS; Wang YC; Ruff LE; Yashar W; Messmer BT; Mould DR
AAPS J; 2018 Sep; 20(6):99. PubMed ID: 30187153
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases.
Kantasiripitak W; Wang Z; Spriet I; Ferrante M; Dreesen E
Expert Rev Clin Pharmacol; 2021 Dec; 14(12):1455-1466. PubMed ID: 35034509
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
Papamichael K; Afif W; Drobne D; Dubinsky MC; Ferrante M; Irving PM; Kamperidis N; Kobayashi T; Kotze PG; Lambert J; Noor NM; Roblin X; Roda G; Vande Casteele N; Yarur AJ; Arebi N; Danese S; Paul S; Sandborn WJ; Vermeire S; Cheifetz AS; Peyrin-Biroulet L;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):171-185. PubMed ID: 35026171
[TBL] [Abstract][Full Text] [Related]
5. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
Papamichael K; Stocco G; Ruiz Del Agua A
Ther Drug Monit; 2023 Oct; 45(5):579-590. PubMed ID: 37012629
[TBL] [Abstract][Full Text] [Related]
6. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
Alsoud D; Moes DJAR; Wang Z; Soenen R; Layegh Z; Barclay M; Mizuno T; Minichmayr IK; Keizer RJ; Wicha SG; Wolbink G; Lambert J; Vermeire S; de Vries A; Papamichael K; Padullés-Zamora N; Dreesen E
Ther Drug Monit; 2024 Jun; 46(3):291-308. PubMed ID: 38648666
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.
Papamichael K; Cheifetz AS
Curr Opin Rheumatol; 2020 Jul; 32(4):371-379. PubMed ID: 32412995
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Drug Monitoring of Biologics in Crohn's Disease.
Grossberg LB; Cheifetz AS; Papamichael K
Gastroenterol Clin North Am; 2022 Jun; 51(2):299-317. PubMed ID: 35595416
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases.
Papamichael K; Vogelzang EH; Lambert J; Wolbink G; Cheifetz AS
Expert Rev Clin Immunol; 2019 Aug; 15(8):837-848. PubMed ID: 31180729
[No Abstract] [Full Text] [Related]
10. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Carman N; Mack DR; Benchimol EI
Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
[TBL] [Abstract][Full Text] [Related]
11. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
Roblin X; Riviere P; Flamant M; Veyrard P; Poullenot F; Paul S; Laharie D
Inflamm Bowel Dis; 2018 Aug; 24(9):1904-1909. PubMed ID: 29726958
[TBL] [Abstract][Full Text] [Related]
12. Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease.
Deben DS; Wong DR; van Bodegraven AA
Expert Opin Drug Metab Toxicol; 2021 Dec; 17(12):1433-1444. PubMed ID: 35023443
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?
Strik AS; Berends SE; Löwenberg M
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):885-891. PubMed ID: 31305158
[No Abstract] [Full Text] [Related]
14. Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics.
Deyhim T; Cheifetz AS; Papamichael K
J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002743
[TBL] [Abstract][Full Text] [Related]
15. Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine.
Lefevre PLC; Shackelton LM; Vande Casteele N
BioDrugs; 2019 Oct; 33(5):453-468. PubMed ID: 31301024
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment.
Dreesen E; Gils A; Vermeire S
Curr Drug Targets; 2018; 19(7):757-776. PubMed ID: 26953243
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?
Hoseyni H; Xu Y; Zhou H
J Clin Pharmacol; 2018 Jul; 58(7):864-876. PubMed ID: 29462502
[TBL] [Abstract][Full Text] [Related]
18. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
[TBL] [Abstract][Full Text] [Related]
19. Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives.
Irving PM; Gecse KB
Gastroenterology; 2022 Apr; 162(5):1512-1524. PubMed ID: 35167865
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.
Papamichael K; Vande Casteele N; Ferrante M; Gils A; Cheifetz AS
Inflamm Bowel Dis; 2017 Sep; 23(9):1510-1515. PubMed ID: 28816757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
